



## Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

May 10, 2023

DUBLIN--(BUSINESS WIRE)--May 10, 2023-- Horizon Therapeutics plc (NASDAQ: HZNP):

### IRISH TAKEOVER PANEL

#### DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

#### BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

### 1. KEY INFORMATION

(a) Full name of discloser: Jeff Himawan

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

*The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.*

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Horizon Therapeutics plc

*Use a separate form for each offeror/offeree*

(d) Status of person making the disclosure:

Person acting in concert with the offeree (namely, a director of the offeree)

*e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)*

(e) Date dealing undertaken:

May 9, 2023

(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

N/A

*If it is a cash offer or possible cash offer, state "N/A"*

### 2. INTERESTS AND SHORT POSITIONS

*If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.*

#### Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (Note 1)

Class of relevant security: Ordinary shares of US\$0.0001 each ("Ordinary Shares")  
(Note 2)

Interests		Short positions	
Number	%	Number	%

(1) Relevant securities owned and/or controlled:	135,400	0.059%	N/A	N/A
--	---------	--------	-----	-----



N/A N/A N/A N/A N/A N/A N/A N/A

**(ii) Exercise**

<b>Class of relevant security</b>	<b>Product description</b> <i>e.g. call option</i>	<b>Exercising/ exercised against</b>	<b>Number of securities</b>	<b>Exercise price per unit</b> (Note 4)
-----------------------------------	---	--------------------------------------	-----------------------------	--

N/A N/A N/A N/A N/A

**(d) Other dealings (including transactions in respect of new securities)**

<b>Class of relevant security</b>	<b>Nature of dealing</b> <i>e.g. subscription, conversion, exercise</i>	<b>Price per unit Details (if applicable)</b> (Note 4)
-----------------------------------	--	---

N/A N/A N/A N/A

**4. OTHER INFORMATION**

**(a) Indemnity and other dealing arrangements**

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

*Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"*

N/A

**(b) Agreements, arrangements or understandings relating to options or derivatives**

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

N/A

**(c) Attachments**

**Is a Supplemental Form 8 attached? YES/NO**

No

**Date of disclosure:** May 10, 2023

**Contact name:** Aidan Milstead

**Telephone number:** +1 224 206 4983

*Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.*

NOTES ON FORM 8.1(c) and (d)(i)

1. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(b) of Part B of the Rules.

2. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.

3. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

4. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

5. See Rule 2.5(d) of Part A of the Rules.

6. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230510005729/en/): <https://www.businesswire.com/news/home/20230510005729/en/>

Aidan Milstead, (224) 206 4983

Source: Horizon Therapeutics plc